Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer

BACKGROUND: Immunotherapy has emerged as a promising treatment strategy in malignant tumors. Inhibitors and neutralizing antibodies targeted PD-1 or PD-L1 show improved clinical outcomes in advanced non-small cell lung cancers (NSCLCs). Previous studies concluded that PD-1 was mainly expressed on ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Fanyi, Zhang, Chuanfen, Xia, Liang, Deng, Senyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841543/
https://www.ncbi.nlm.nih.gov/pubmed/35261880
http://dx.doi.org/10.21037/tcr-21-1644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841543/
https://www.ncbi.nlm.nih.gov/pubmed/35261880
http://dx.doi.org/10.21037/tcr-21-1644

Ejemplares similares